Yair Gazitt
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments 19
- Hematopoietic Stem Cell Transplantation 19
- Immunology top 5%
- Immunotherapy and Immune Responses 19
- T-cell and B-cell Immunology 12
- Oncology top 5%
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 12
- Molecular Biology top 5%
- Cell death mechanisms and regulation 12
-
- Erythrocyte Function and Pathophysiology 12
-
- Lymphoma Diagnosis and Treatment 10
- Co-authors
- Cagla AkaySusan G. HilsenbeckQun LiuItzhak OhadCharlotte FriendSun Jin ChoiAbraham LoyterPaul Shaughnessy
- Cited by
- HematologyImmunologyOncology
- Journals
- Journal of Biological Chemistry (1 paper)Journal of Clinical Investigation (3 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- United StatesIsraelSweden
In The Last Decade
Yair Gazitt
109 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 109
- Hematology 1.1k
- Immunology 678
- Oncology 860
- Genetics 264
- Molecular Biology 1.6k
Countries citing papers authored by Yair Gazitt
This map shows the geographic impact of Yair Gazitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yair Gazitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yair Gazitt more than expected).
Fields of papers citing papers by Yair Gazitt
This network shows the impact of papers produced by Yair Gazitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yair Gazitt. The network helps show where Yair Gazitt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yair Gazitt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 118 | |
| 2 | 2007 | 43 | |
| 3 | 2006 | 16 | |
| 4 | Mobilization of type1 and type2 dendritic cells (DC1 and DC2) in non-Hodgkin’s lymphoma (NHL) patients mobilized with G-CSF, GM-CSF or GM-CSF followed by G-CSF | 2004 | 2 |
| 5 | 2002 | 43 | |
| 6 | 2001 | 21 | |
| 7 | 2001 | 23 | |
| 8 | 2001 | 25 | |
| 9 | 2001 | 142 | |
| 10 | 2001 | 41 | |
| 11 | 2001 | 20 | |
| 12 | 2000 | 31 | |
| 13 | 2000 | 17 | |
| 14 | A phase I-II clinical trial with a combination of gemcitabine (GEMZAR) and paclitaxel (TAXOL) for the treatment of refractory multiple myeloma (MM) patients | 2000 | 3 |
| 15 | 1999 | 55 | |
| 16 | 1999 | 59 | |
| 17 | 1994 | 48 | |
| 18 | 1992 | 2 | |
| 19 | 1992 | 1 | |
| 20 | 1991 | 5 |
About Yair Gazitt
Yair Gazitt is a scholar working on Hematology, Immunology and Genetics, having authored 110 papers that have together received 3.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (19 papers), Immunotherapy and Immune Responses (19 papers), Hematopoietic Stem Cell Transplantation (19 papers), Chronic Lymphocytic Leukemia Research (12 papers), Erythrocyte Function and Pathophysiology (12 papers), Cell death mechanisms and regulation (12 papers), T-cell and B-cell Immunology (12 papers) and Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Hematology (1.1k citations), Immunology (678 citations) and Oncology (860 citations). Yair Gazitt has collaborated with scholars based in United States, Israel and Sweden. Frequent co-authors include Cagla Akay, Susan G. Hilsenbeck, Qun Liu, Itzhak Ohad, Charlotte Friend, Sun Jin Choi, Abraham Loyter, Paul Shaughnessy, Qun Liu and Melissa Alsina. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.